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ABSTRACT
The microsomal prostaglandin E2 synthase (mPGES)-1 is one of
the terminal isoenzymes of prostaglandin (PG) E2 biosynthesis.
Pharmacological inhibitors of mPGES-1 are proposed as an alter-
native to nonsteroidal anti-inflammatory drugs. We recently pre-
sented the design and synthesis of a series of pirinixic acid deriv-
atives that dually inhibit mPGES-1 and 5-lipoxygenase. Here, we
investigated the mechanism of mPGES-1 inhibition, the selectivity
profile, and the in vivo activity of -(n-hexyl)-substituted pirinixic
acid [YS121; 2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-
2-ylthio)octanoic acid)] as a lead compound. In cell-free assays,
YS121 inhibited human mPGES-1 in a reversible and noncompet-
itive manner (IC50  3.4 M), and surface plasmon resonance
spectroscopy studies using purified in vitro-translated human
mPGES-1 indicate direct, reversible, and specific binding to
mPGES-1 (KD  10–14 M). In lipopolysaccharide-stimulated
human whole blood, PGE2 formation was concentration depen-
dently inhibited (IC50 2 M), whereas concomitant generation of
the cyclooxygenase (COX)-2-derived thromboxane B2 and 6-keto
PGF1 and the COX-1-derived 12(S)-hydroxy-5-cis-8,10-trans-
heptadecatrienoic acid was not significantly reduced. In carra-
geenan-induced rat pleurisy, YS121 (1.5mg/kg i.p.) blocked exudate
formation and leukocyte infiltration accompanied by reduced pleural
levels of PGE2 and leukotriene B4 but also of 6-keto PGF1. Taken
together, these results indicate that YS121 is a promising in-
hibitor of mPGES-1 with anti-inflammatory efficiency in human
whole blood as well as in vivo.
Prostaglandins (PGs) are potent lipid mediators that pro-
mote inflammatory reactions but also possess homeostatic
functions (Funk, 2001). Their biosynthesis involves oxygen-
ation of arachidonic acid by cyclooxygenase (COX)-1 or -2 to
PGH2 and further conversion by PG synthases to the respec-
tive PGs (Funk, 2001). Inhibition of COX-1 and -2 by nonste-
roidal anti-inflammatory drugs and selective suppression of
COX-2 by coxibs are common and effective strategies for the
therapy of inflammatory disorders, fever, and pain, but their
long-term use is associated with severe side effects (Rains-
ford, 2007). Unselective COX-1/2 inhibitors may cause gas-
tric toxicity, whereas an increased cardiovascular risk in
This work was supported in part by Carl Zeiss GmbH (to C.P.).
Article, publication date, and citation information can be found at
http://jpet.aspetjournals.org.
doi:10.1124/jpet.109.160663.
ABBREVIATIONS: PG, prostaglandin; COX, cyclooxygenase; Tx, thromboxane; mPGES, microsomal prostaglandin E2 synthase; pirinixic acid,
(2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)acetic acid; YS121, 2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic
acid; PPAR, peroxisome proliferator-activated receptor; MD52, 2-(2-chlorophenyl)-1H-phenanthro[9,10-d]-imidazole; DMSO, dimethyl sulfoxide;
CV4151, (E)-7-phenyl-7-(3-pyridyl)-6-heptenoic acid; MK-886, 3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic
acid; RP, reverse phase; HPLC, high-performance liquid chromatography; RM, reaction mixture; PBS, phosphate-buffered saline; SPR, surface
plasmon resonance; 12-HHT, 12(S)-hydroxy-5-cis-8,10-trans-heptadecatrienoic acid; PAGE, polyacrylamide gel electrophoresis; LT, leukotriene;
ANOVA, analysis of variance; HSD, honestly significant difference; ELISA, enzyme-linked immunosorbent assay.
0022-3565/10/3323-840–848$20.00
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 332, No. 3
Copyright © 2010 by The American Society for Pharmacology and Experimental Therapeutics 160663/3557357
JPET 332:840–848, 2010 Printed in U.S.A.
840
patients after long-term intake of coxibs was evident, appar-
ently due to an imbalance of prothrombotic COX-1-derived
thromboxane (Tx) A2 and antithrombotic and vasodilatory
COX-2-derived PGI2 (McGettigan and Henry, 2006). Selec-
tive suppression of proinflammatory PGE2 biosynthesis by in-
hibition of microsomal prostaglandin E2 synthase (mPGES)-1
without affecting the biosynthesis of homeostatic prostanoids
(e.g., PGI2) might overcome these limitations.
Among the three isomeric PGE2 synthases, the inducible
isoform mPGES-1 is essentially involved in massive PGE2
formation, for example, during inflammation, fever, and pain
(Samuelsson et al., 2007). mPGES-1, a homotrimeric mem-
brane protein of the endoplasmic reticulum (Jegerscho¨ld et
al., 2008), commonly acts in concert with COX-2 (Murakami
et al., 2000) and is strongly up-regulated by proinflammatory
stimuli (e.g., interleukin-1 and lipopolysaccharide) as well
as under various pathological conditions (e.g., chronic inflam-
mation, pain, fever, atherosclerosis, stroke, anorexia, and
tumorigenesis) (Samuelsson et al., 2007). Genetic or pharma-
cological inhibition of mPGES-1 showed efficiency compara-
ble with that of nonsteroidal anti-inflammatory drugs in
animal models of inflammation, fever, and pain, while being
essentially free of gastrointestinal adverse effects (Samuels-
son et al., 2007; Xu et al., 2008). Deletion of mPGES-1 was
not associated with cardiovascular complications, i.e., hyper-
tension or thrombogenesis, at least in the absence of risk
factors such as chronic salt loading (Wang et al., 2008).
Despite the increasing number of scientific reports and
patents revealing novel mPGES-1 inhibitors (Friesen and
Mancini, 2008; Koeberle and Werz, 2009), studies addressing
the mechanistic basis and clinical relevance of mPGES-1
inhibition are rare (Xu et al., 2008; Koeberle et al., 2009b).
Many mPGES-1 inhibitors with high efficiency in cell-free
assays exhibit a strong loss of potency in cell-based assays, in
particular in whole blood (Friesen and Mancini, 2008). In
addition, these compounds fail to inhibit rodent mPGES-1 and
thus are inactive in in vivo models based on mice or rats. We
recently showed that target-oriented structural derivatization
of pirinixic acid (2-(4-chloro-6-(2,3-dimethylphenylamino)pyri-
midin-2-ylthio)acetic acid) (Fig. 1) led to -substituted piri-
nixic acid derivatives such as YS121 (Fig. 1), which inhibits
mPGES-1 (IC50  3.4 M) (Koeberle et al., 2008b) and 5-li-
poxygenase (IC50 4.1 and 6.5 M in cell-based and cell-free
assays, respectively) (Werz et al., 2008) and activates peroxi-
some proliferator-activated receptor (PPAR)- and - (EC50 1
and 3.6 M, respectively) (Rau et al., 2008). Here, we inves-
tigated the biochemical interaction of YS121 with mPGES-1.
Moreover, we analyzed the interference of YS121 with pro-
stanoid biosynthesis in human whole blood, and we assessed
the anti-inflammatory efficacy in the carrageenan-induced
rat pleurisy model.
Materials and Methods
Materials. YS121 was synthesized as reported previously (Koe-
berle et al., 2008b; Werz et al., 2008). Pirinixic acid was purchased
from Sigma-Aldrich (Deisenhofen, Germany). The mPGES-1 inhibi-
tor MD52 was synthesized according to Coˆte´ et al. (2007). The com-
pounds were dissolved in DMSO and kept in the dark at 20°C, and
freezing/thawing cycles were kept to a minimum. For animal studies,
the compounds were dissolved in DMSO and diluted with saline to
achieve a final DMSO concentration of 4%. The thromboxane syn-
thase inhibitor CV4151 (Kato et al., 1985) was kindly provided by Dr.
S. Laufer (University of Tu¨bingen, Tu¨bingen, Germany). The anti-
body against human mPGES-1 was from Cayman Chemical (Ann
Arbor, MI). Antibodies against COX-2 and -actin were obtained
from Sigma-Aldrich. Materials used were as follows: Dulbecco’s mod-
ified Eagle’s high glucose (4.5 g/l) medium, penicillin, streptomycin,
and trypsin/EDTA solution from PAA Laboratories GmbH (Coelbe,
Germany); PGH2 from Larodan (Malmo¨, Sweden); 11-PGE2, MK-
886, PGB1, and enzyme immunoassay from Cayman Chemical;
N-formyl-methionyl-leucyl-phenylalanine from Alexis Corpora-
tion (Lo¨rrach, Germany); 1-lauroyl-2-hydroxy-sn-glycero-3-phos-
phocholine from Anatrace (Maumee, OH); -carrageenan type IV
isolated from Gigartina aciculaire and Gigartina pistillata and indo-
methacin was from Sigma-Aldrich (Milan, Italy); [3H]PGE2 was from
PerkinElmer Life Sciences (Milan, Italy); and PGE2 antibody was
from Sigma-Aldrich. All other chemicals were obtained from Sigma-
Aldrich (Deisenhofen, Germany) unless stated otherwise.
Cells. Human lung carcinoma A549 cells and murine RAW 264.7
cells were cultured in Dulbecco’s modified Eagle’s high glucose (4.5
g/l) medium supplemented with heat-inactivated fetal calf serum
(10%, v/v), penicillin (100 U/ml), and streptomycin (100 g/ml) at
37°C in a 5% CO2 incubator. After 3 days, confluent A549 cells were
detached using 1  trypsin/EDTA solution and reseeded at 2  106
cells in 20 ml of medium in 175-cm2 flasks.
Animals.Male adult Wistar Han rats (200–220 g; Harlan, Milan,
Italy) were housed in a controlled environment and provided with
standard rodent chow and water. Animal care complied with Italian
regulations on protection of animals used for experimental and other
scientific purpose (Ministerial Decree 116192) as well as with the
European Economic Community regulations (Official Journal of Eu-
ropean Community L 358/1 12/18/1986).
Preparation of Crude mPGES-1 in Microsomes of A549
Cells and Determination of PGE2 Synthase Activity. Prepara-
tion of A549 cells and determination of mPGES-1 activity was per-
formed as described previously (Koeberle et al., 2008a). In brief, cells
were treated with 1 ng/ml interleukin-1 for 48 h at 37°C and 5%
CO2. After sonification, the homogenate was subjected to differential
centrifugation at 10,000g for 10 min and 174,000g for 1 h at 4°C. The
pellet (microsomal fraction) was resuspended in 1 ml of homogeni-
zation buffer (0.1 M potassium phosphate buffer, pH 7.4, 1 mM
phenylmethanesulfonyl fluoride, 60 g/ml soybean trypsin inhibitor,
1 g/ml leupeptin, 2.5 mM glutathione, and 250 mM sucrose), and
the total protein concentration was determined. Microsomal mem-
branes were diluted in potassium phosphate buffer (0.1 M, pH 7.4)
containing 2.5 mM glutathione. Test compounds or vehicle were
added, and after 15 min at 4°C, the reaction (100 l total volume)
was initiated by addition of PGH2 (20 M, final concentration). After
1 min at 4°C, the reaction was terminated using stop solution (100
l; 40 mM FeCl2, 80 mM citric acid, and 10 M 11-PGE2 as internalFig. 1. Chemical structures of pirinixic acid and YS121.
Inhibition of mPGES-1 by -(n-Hexyl)-pirinixic Acid 841
standard). PGE2 was separated by solid-phase extraction and ana-
lyzed by RP-HPLC as described previously (Koeberle et al., 2008a).
Cell-Free Expression of Human mPGES-1. Human mPGES-1
was obtained by the continuous-exchange cell-free expression system
according to Schwarz et al. (2007). This system comprises a reaction
mixture (RM) that contains the Escherichia coli S30 extract (derived
from the A19 strain), T7 polymerase, tRNAs, pyruvate kinase, and
the template DNA for human mPGES-1 (cloned in the pBH4 vector
derived from pET19b; Novagen, Madison, WI). The RM is dialyzed
against the feeding mixture that supplies amino acids, energy equiv-
alents acetyl phosphate and phosphoenol pyruvate, and nucleotides.
Reactions were incubated at 30°C for up to 20 h. Protein synthesis
takes place in the RM and up to 1.5 mg of mPGES-1/ml RM can be
obtained. mPGES-1 was resuspended in 50 mM potassium phos-
phate buffer, pH 7.4, 1 mM glutathione, 10% glycerol, and 2% (w/v)
1-lauroyl-2-hydroxy-sn-glycero-3-phosphocholine (LysoFos12 choline;
Anatrace, Maumee, OH) for 2 h at 30°C, and insoluble parts were
removed by centrifugation (10,000g 10 min, 10°C).
Determination of the Activity of In Vitro-Translated
mPGES-1. After resolubilization, the in vitro-translated mPGES-1
was incorporated into liposomes, which were prepared by sonifica-
tion of phosphatidylethanolamine [0.15 mM in potassium phosphate
buffer (0.1 M), pH 7.4, containing 2.5 mM glutathione] for 1 min on
ice. The PGE2 synthase activity of these liposomal preparations was
determined as described for microsomal preparations of interleukin-
1-stimulated A549 cells. The activity of the in vitro-translated
mPGES-1 was 0.5 U/mg (where 1 U is defined as the amount of
enzyme that forms 1 mol of PGE2/min under standard assay con-
ditions, i.e., 20 M PGH2, 2.5 mM glutathione, 4°C, pH 7.4) that
corresponds to 0.5 mol of PGE2 formed/mg of protein/min.
Determination of PGE2 Formation in Intact RAW 264.7
Cells. Expression of mPGES-1 in RAW 264.7 cells was induced by
incubation with lipopolysaccharide (1 g/ml) for 20 h. Cells were
washed twice with PBS, resuspended in PBS (106/ml), and preincu-
bated with the indicated compounds at 37°C for 10 min. PGE2
formation was started by the addition of arachidonic acid (1 M). The
reaction was stopped after 15 min at 37°C, and the samples were put
on ice. For quantification of PGE2, samples were extracted, fraction-
ated by HPLC, and then quantified using a PGE2 High Sensitivity
EIA Kit (Assay Designs, Ann Arbor, MI) according to the manufac-
turer’s protocol.
SPR Spectroscopy. In vitro-translated mPGES-1 (100 g/ml) in
10 mM sodium acetate buffer (pH 6.0) was coupled to a carboxy-
methylated dextran surface (CM-5 chip; GE Healthcare, Munich,
Germany) using a standard amine coupling procedure according to
the manufacturer’s instructions. Flow cell 1 on the chip was not
altered (reference), whereas on flow cell 2, mPGES-1 (236 fmol/mm2
corresponding to 4700 resonance units) or cathepsin G (112 fmol/
mm2 corresponding to 2500 resonance units, used as negative con-
trol) was immobilized. Then the chip surface was equilibrated by a
continuous flow of assay buffer (10 mM HEPES, 150 mM NaCl,
0.01% surfactant P20, and 1% DMSO, pH 7.4), the stock solutions of
test compounds in DMSO were diluted into assay buffer, and mea-
surements were performed on a BIAcore X device (GE Healthcare) at
25°C and a flow rate of 30 l/min. After the association of the test
compounds to flow cell 2, the mobile phase was replaced by assay
buffer, and the dissociation was monitored. The binding profiles were
obtained after subtracting the response signals of the untreated
reference cell 1, and the resulting sensograms were processed by
using automatic correction for nonspecific bulk refractive index ef-
fects (BIAevaluation software, version 3.1).
To obtain the dissociation constants from the equilibrium binding
data, two different fitting models were adopted. First, the change in
the equilibrium amount of compound bound as a function of the
concentration of compound was fitted to the equation for a simple 1:1
binding model [Req  (Rmax  [compound]/(KD 	 [compound])],
where Req is the equilibrium response, Rmax is the maximum re-
sponse, and KD is the dissociation constant. Alternatively, Scatchard
plot analysis was used to estimate KD values. Kinetic analysis were
performed using BIAevaluation software (version 3.1) by fitting an
integrated rate equation describing a 1:1 Langmuir interaction si-
multaneously to the entire concentration range for YS121. This fit
yielded the association rate ka, the dissociation rate kd, and the
dissociation constant KD (Roden and Myszka, 1996; Karlsson and
Fa¨lt, 1997). The quality of the fit was determined by the 
2 values as
well as by the magnitude and distribution of the residuals.
Determination of Prostanoid Formation in Human Whole
Blood. Peripheral blood from healthy adult volunteers, who had not
received any medication for at least 2 weeks under informed consent,
was obtained by venipuncture and collected in syringes containing
heparin (20 U/ml). For determination of PGE2 and 6-keto PGF1,
aliquots of whole blood (0.8 ml) were mixed with CV4151 (1 M) and
with aspirin (50 M). For determination of TxB2, aliquots of whole
blood (0.5 ml) were used without addition of CV4151. A total volume
of 1 ml was adjusted with sample buffer (10 mM potassium phos-
phate buffer, pH 7.4, 3 mMKCl, 140 mMNaCl, and 6 mM d-glucose).
After preincubation with the indicated compounds for 5 min at room
temperature, the samples were stimulated with lipopolysaccharide
(10 g/ml) for 5 h at 37°C. Prostanoid formation was stopped on ice,
the samples were centrifuged (2300g, 10 min, 4°C), and 6-keto PGF1
and TxB2 were quantified in the supernatant using High Sensitivity
EIA Kits for 6-keto PGF1 and TxB2, respectively, according to the
manufacturer’s protocols. PGE2 was determined as described previ-
ously (Koeberle et al., 2009b). In brief, the supernatant was acidified
with citric acid (30 l, 2 M), and after centrifugation (2300g, 10 min,
4°C), solid-phase extraction, and RP-HPLC, analysis of PGE2 was
performed to isolate PGE2. The PGE2 peak (3 ml), identified by
coelution with the authentic standard, was collected, and acetonitrile
was removed under a nitrogen stream. The pH was adjusted to 7.2 by
addition of 10 PBS buffer, pH 7.2 (230 l) before PGE2 contents
were quantified using a PGE2 High Sensitivity EIA Kit according to
the manufacturer’s protocol.
For determination of 12(S)-hydroxy-5-cis-8,10-trans-heptadeca-
trienoic acid (12-HHT), human whole blood (2 ml) was preincubated
with the indicated compounds at 37°C for 5 min, and formation of
12-HHT was initiated by addition of 30 M Ca2	-ionophore A23187
and 100 M arachidonic acid. After 10 min at 37°C, the reaction was
stopped on ice, and the samples were centrifuged (600g, 10 min, 4°C).
Aliquots of the resulting plasma (500 l) were then mixed with 2 ml
of methanol, and 200 ng of PGB1 was added as internal standard.
The samples were placed at 20°C for 2 h and centrifuged again
(600g, 15 min, 4°C). The supernatants were collected and diluted
with 2.5 ml of PBS, and 75 l of 1 N HCl was added. Formed 12-HHT
was extracted and analyzed by HPLC as described previously (Albert
et al., 2002).
SDS-PAGE and Western Blot. Cells (4  106 cells) were resus-
pended in 50 l of PBS buffer (pH 7.2), mixed with the same volume
of 2 SDS/PAGE sample loading buffer [20 mM Tris-HCl, pH 8, 2
mM EDTA, 5% (m/v) SDS, and 10% (v/v) -mercaptoethanol], and
boiled for 5 min at 95°C. Aliquots (20 l) corresponding to equiva-
lents of 0.8  106 cells were mixed with 4 l of glycerol-0.1% brom-
phenol blue (1:1, v/v), and proteins were separated by SDS-PAGE.
After electroblotting to nitrocellulose membrane (GE Healthcare)
and blocking with 5% bovine serum albumin for 1 h at room temper-
ature, membranes were washed and incubated with primary anti-
bodies overnight at 4°C. The membranes were washed and incubated
with a 1:1000 dilution of alkaline phosphatase-conjugated immuno-
globulin G for 3 h at room temperature. After washing, proteins were
visualized with nitro blue tetrazolium and 5-bromo-4-chloro-3-
indolylphosphate.
Carrageenan-Induced Pleurisy in Rats. YS121 (1.5 mg/kg) or
indomethacin (5 mg/kg) was given intraperitoneally 30 min before
carrageenan. A group of male rats received the vehicle (DMSO, 4%,
intraperitoneally) 30 min before carrageenan. Rats were anesthe-
tized with enflurane 4% mixed with 0.5 l/min O2 and 0.5 l/min N2O
and submitted to a skin incision at the level of the left sixth inter-
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costal space. The underlying muscle was dissected, and saline (0.2
ml) or 1% -carrageenan type IV (w/v, 0.2 ml) was injected into the
pleural cavity. The skin incision was closed with a suture, and the
animals were allowed to recover. At 4 h after the injection of carra-
geenan, the animals were killed by inhalation of CO2. The chest was
carefully opened, and the pleural cavity was rinsed with 2 ml of
saline solution containing heparin (5 U/ml). The exudate and wash-
ing solution were removed by aspiration, and the total volume was
measured. Any exudate that was contaminated with blood was dis-
carded. The amount of exudates was calculated by subtracting the
volume injected (2 ml) from the total volume recovered. Leukocytes
in the exudates were resuspended in PBS and counted with an
optical light microscope in a Burker’s chamber after vital trypan blue
staining.
The amounts of PGE2, LTB4, and 6-keto PGF1 in the supernatant
of centrifuged exudate (800g for 10 min) were assayed by radioim-
munoassay (PGE2) and enzyme immunoassay (LTB4 and 6-keto
PGF1), respectively (Cayman Chemical), according to the manufac-
turer’s protocol. The results are expressed as nanograms per rat and
represent the mean  S.E. of 10 rats.
Statistics. Data are expressed as mean  S.E. Concentration-
response curves were fitted to a one-side binding competition equa-
tion, and IC50 values were determined using SigmaPlot 9.0 (Systat
Software Inc., San Jose, CA). The program GraphPad Instat (Graph-
Pad Software Inc., San Diego, CA) was used for statistical compari-
sons. Statistical evaluation of the data was performed by one-way or
two-way ANOVAs for independent or correlated samples followed by
Tukey HSD post hoc tests. P  0.05 was considered significant.
Results
YS121 Is a Reversible and Noncompetitive Inhibitor
of mPGES-1. In agreement with previous studies (Koeberle
et al., 2008b), YS121 concentration-dependently inhibited
the mPGES-1-mediated conversion of PGH2 to PGE2 (IC50 of
3.4 M, essentially complete inhibition at 30 M) in micro-
somal preparations of interleukin-1-stimulated human
A549 cells (Fig. 2A). Suppression of other PGs such as PGD2
could not be observed (data not shown). As observed for other
mPGES-1 inhibitors that fail to inhibit the rodent enzyme
(Friesen and Mancini, 2008), YS121 hardly affected the ac-
tivity of mPGES-1 in murine RAW264.7 macrophages (30%
inhibition at 30 M) and MD52 (2 M, reference mPGES-1
inhibitor) did not significantly inhibit PGE2 formation (data
not shown). To investigate whether YS121 inhibits human
mPGES-1 activity in a reversible manner, washout experi-
ments were performed. Thus, microsomes from IL-1-stimu-
lated A549 cells were preincubated with YS121 at 1 or 10 M
for 15 min. The sample containing 10 MYS121 was split, and
one aliquot was diluted 10-fold to obtain a final inhibitor con-
centration of 1 M. Then, PGE2 formation was initiated by
addition of PGH2. At a concentration of 1 M, YS121 did not
significantly reduce PGE2 formation (16.9  4.8% inhibition,
P  0.05), whereas 10 M YS121 significantly inhibited PGE2
synthesis by 60.6  5% (P  0.001) (Fig. 2B). Dilution of the
sample containing 10 M YS121 restored mPGES-1 activity
(Fig. 2B), suggesting a reversible mode of inhibition. Although
the diluted sample still contained 1 MYS121, PGE2 formation
was entirely reversed for unknown reasons.
Next, we attempted to define whether YS121 competes
with the substrate (PGH2) to inhibit mPGES-1 activity. In
the mPGES-1 assay using microsomes of IL-1-stimulated
A549 cells (total protein  87 g/ml), the substrate concen-
tration was varied over a concentration range of 10 to 50 M
PGH2, and the rate of PGE2 formation was determined. Fit-
ting of the data for the noninhibited reaction to a Michaelis-
Menten kinetic model (Fig. 2C) and reciprocal linear regres-
Fig. 2. YS121 inhibits mPGES-1 in a reversible and
noncompetitive manner. A, microsomal prepara-
tions of interleukin-1-stimulated A549 cells were
preincubated with vehicle (DMSO, w/o) or the test
compounds at the indicated concentrations for 15
min at 4°C, and the reaction was started with 20
M PGH2. After 1 min at 4°C, the reaction was
terminated using a stop solution containing FeCl2
and 11-PGE2 (1 nmol) as internal standard. The
100% values in the individual experiments are in
the range of 3 to 4 g/ml PGE2 and correspond to
enzyme activities of 6 to 18 mol of PGE2/mg of
protein/min. MK-886, used as control, inhibited
PGE2 formation with an IC50 of 2.2 M. Data are
given as means  S.E. (n  3–4). , P  0.001
versus vehicle (0.1% DMSO) control, ANOVA 	
Tukey HSD post hoc tests. B, reversibility of
mPGES-1 inhibition by YS121. Microsomal prepa-
rations of interleukin-1-stimulated A549 cells
were preincubated with 10 M YS121 for 15 min at
4°C. An aliquot was diluted 10-fold to obtain an
inhibitor concentration of 1 M. Then 20 M PGH2
was added (no dilution), all samples were incubated
for 1 min on ice, and PGE2 formation was analyzed
by RP-HPLC as described. Data are given as
means  S.E. (n  3–4). , P  0.001. C, the
activity of mPGES-1 was determined at different
PGH2 and YS121 concentrations as indicated (left),
and Lineweaver-Burk analysis (right) was per-
formed. Data are given as means  S.E. (n  2–4).
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sion analysis (Lineweaver-Burk plot) (Fig. 2C) yielded Km
values of 54 and 30 M and Vmax values of 2.6 and 1.9
nmol/min, respectively. Variation of the PGH2 concentration
(10–50 M) and subsequent Lineweaver-Burk analysis indi-
cate a noncompetitive type of inhibition by YS121 (Fig. 2C).
These results preclude preferential binding of YS121 to the
PGH2 binding pocket of mPGES-1.
Characterization of the Binding of YS121 to mPGES-1
by SPR Spectroscopy. The direct (physical) interaction of
YS121 with human mPGES-1 was analyzed using SPR spec-
troscopy. Purified in vitro-translated mPGES-1 (236 fmol of
mPGES-1/mm2) with a specific activity of 0.5 U/mg (when
tested in a cell-free assay in which mPGES-1 was first em-
bedded in liposomes and then supplied with PGH2 as sub-
strate) was immobilized to one of the two flow cells of the
CM5 sensor chip. YS121 was diluted into assay buffer
(1.25–10 M) and sequentially injected over the chip surface.
For calculating the binding responses, the response of the
untreated reference cell was subtracted from the response of
the mPGES-1 surface. Figure 3A shows the corrected senso-
grams for different concentrations of YS121 (top left panel).
The maximal concentration of YS121 was limited to 10 M
because unspecific (superstoichiometric) binding to mPGES-1
and to the reference surface was observed at concentrations
10 M. The unspecific binding at high analyte concentra-
tions could be minimized by inclusion of 0.01% detergent
(P20) in the running buffer, at least at concentrations of
YS121 10 M.
To discriminate unspecific binding behavior of YS121, the
structurally related lead compound pirinixic acid, which did not
inhibit mPGES-1 activity (Koeberle et al., 2008b), was ana-
lyzed. Pirinixic acid failed to interfere with mPGES-1 up to 40
M (Fig. 3B). Furthermore, YS121 (up to 20 M) failed to bind
to an immobilized reference protein, i.e., cathepsin G (Fig. 3C)
(previously used in SPR studies; U. Siemoneit and O. Werz,
unpublished data), which is also not functionally affected by
YS121 (data not shown). Taken together, these results indicate
that YS121 binds directly and selectively to mPGES-1.
For determination of the equilibrium binding constants of
YS121, we fitted the equilibrium response (Req) as a function
of the analyte concentration to a 1:1 interaction model, and
the fit was superimposed over each data set (Fig. 3D). Dis-
sociation constants (KD) of 14 and 11 M were calculated
from the nonlinear fit (top panel) and for the Scatchard plot
(bottom panel), respectively. The kinetic parameters (rate
constants) of the association and dissociation phases were
obtained by fitting the data sets to a 1:1 Langmuir binding
model using BIAevaluation software (version 3.1) (Rich et al.,
2001). The dissociation constant KD was calculated from the
rate constants (kd/ka  0.14 s
1/13,900 M1 s1  KD  10
M) and is consistent with the KD determined by equilibrium
measurements (Fig. 3A). The actual KD values are similar to
the IC50 value of 3.4 M obtained in the cell-free mPGES-1
activity assay, supporting a functional correlation between
mPGES-1 binding and inhibition.
Effects of YS121 on Eicosanoid Formation in Human
Whole Blood. Many potent mPGES-1 inhibitors constitute
highly lipophilic molecules with strong albumin-binding fea-
tures and this abolishes their efficiency in biological assays
(Friesen and Mancini, 2008). The effectiveness of YS121 to
inhibit cellular COX-2-derived PGE2 biosynthesis was inves-
tigated in a human whole blood assay. The COX-2 selective
inhibitor celecoxib and the mPGES-1 inhibitor MD52 were
used as controls. First, heparinized blood was preincubated
with the thromboxane synthase inhibitor CV4151 (1 M) and
the test compounds and stimulated with lipopolysaccharide
(10 g/ml) for 5 h, and then formed PGE2 was separated by
RP-HPLC and quantified by ELISA (Koeberle et al., 2009b).
In agreement with previous studies, MD52 (which inhibits
human mPGES-1 with an IC50  87 nM in cell-free assays)
(Coˆte´ et al., 2007) maximally suppressed PGE2 synthesis in
whole blood by 48.3  7.7% at high concentrations (2–6 M),
whereas celecoxib (20 M) efficiently inhibited PGE2 forma-
tion under these conditions (78.3  8.4%; IC50  0.87 M)
(Riendeau et al., 2001). YS121 concentration-dependently in-
hibited PGE2 formation with an IC50 value of 3 M (Fig. 4A),
and, in analogy with MD52, complete inhibition of PGE2 syn-
thesis could not be achieved even at 30 M. Of interest, the
COX-2/PGI2 synthase-derived 6-keto PGF1 (a stable metab-
olite of PGI2) was not significantly reduced (Fig. 4A). In the
absence of CV4151, PGE2 synthesis was only moderate but
still was suppressed by YS121 (IC505 M; data not shown),
whereas the concomitant, strong generation of COX-2-de-
rived TxB2 was not inhibited (Fig. 4A). These data suggest
that YS121 does not suppress PGH2 formation (i.e., by COX
inhibition) but instead inhibits transformation of PGH2 to
PGE2. Furthermore, we investigated the effects of YS121 in
another human whole-blood assay under stimulation condi-
tions, designed to analyze COX-1 activity. After preincuba-
tion with YS121, Ca2	-ionophore plus arachidonic acid (100
M) was added to induce 12-HHT formation (predominantly
produced by constitutively expressed COX-1 under these ex-
perimental conditions). YS121 failed to significantly sup-
press 12-HHT formation up to 30 M (Fig. 4B).
Effects of YS121 on Interleukin-1-Mediated COX-2/
mPGES-1 Expression. -Alkyl-substituted pirinixic acid
derivatives such as YS121 are dual agonists of PPAR and 
(Rau et al., 2008). Because PPAR/ agonists were described
to down-regulate the expression of COX-2 (Inoue et al., 2000;
Grau et al., 2006) and mPGES-1 (Cheng et al., 2004), we
analyzed the effects of YS121 on the expression of COX-2 and
mPGES-1 protein in IL-1-treated A549 cells. Stimulation
with interleukin-1 (1 ng/ml) led to increased expression of
mPGES-1 and of COX-2 protein within 24 h compared with
that in unstimulated cells, which were not affected by YS121
(10 M) (Fig. 5). Incubation in the presence of YS121 (10 M)
led to a decrease in COX-2 expression after 24 to 48 h, whereas
expression of mPGES-1 was not affected within 48 h.
YS121 Suppresses Carrageenan-Induced Pleurisy in
Rats. The anti-inflammatory effectiveness of YS121 was as-
sessed in vivo using carrageenan-induced pleurisy in rats.
Injection of carrageenan into the pleural cavity of rats
(DMSO 4% group) elicited an inflammatory response within
4 h, characterized by the accumulation of fluid that contained
large numbers of inflammatory cells (Table 1). Based on in
vivo studies performed previously (Feisst et al., 2009; Rossi
et al., 2009) with compounds having similar pharmacological
profiles in vitro, the dose of YS121 was chosen at 1.5 mg/kg
i.p., 30 min before carrageenan. YS121 significantly inhibited
the inflammatory response as demonstrated by the signifi-
cant attenuation of exudate formation (62%) and cell infiltra-
tion (40%). Indomethacin (5 mg/kg) also reduced exudate
formation and cell infiltration (75 and 65%, respectively)
(Table 1). In comparison with the corresponding exudates
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from DMSO-treated rats, exudates of YS121-treated animals
exhibited decreased PGE2 levels (36% inhibition), whereas
indomethacin almost completely suppressed PGE2 (88%) as
well as 6-keto PGF1 (94%) levels as expected. On the other
hand, indomethacin failed to significantly reduce LTB4 lev-
els, which were lowered by YS121 (48% inhibition), seem-
ingly because of direct inhibition of 5-lipoxygenase (Werz et
al., 2008). We were surprised to find that YS121 also reduced
the levels of 6-keto PGF1 (45% inhibition).
Discussion
We showed before that -substituted pirinixic acid deriva-
tives (that activate PPAR/) dually inhibit mPGES-1 and
Fig. 3. Analysis of the interaction of YS121 with mPGES-1 by SPR spectroscopy. The test compounds at the indicated concentrations were injected
sequentially over the mPGES-1 (236 fmol/mm2) or the cathepsin G (112 fmol/mm2) surface as well as over the untreated reference surface at a
continuous flow of 30 l/min. Sensograms were obtained by subtracting the response of the reference cell from the cell with the immobilized enzyme.
A, binding of YS121 to mPGES-1. For kinetic evaluation of inhibitor binding, the data were fitted to a 1:1 Langmuir binding model, and the results
are shown by solid lines (top). The bottom panel shows the distribution of the residuals to allow evaluation of the quality of the fitting model. The
residuals are the difference between the response data (observed value) and the estimated value, derived from the fitting model adopted to represent
the response. B, binding of pirinixic acid (PA) to mPGES-1. C, binding of YS121 to cathepsin G. Sensograms are representative of three independent
experiments. D, the equilibrium responses Req were plotted against the indicated concentrations of YS121 (top), and the corresponding Scatchard plots
are given (bottom). The solid lines represent the nonlinear fit to a simple 1:1 interaction model. Data are given as means S.E. (n 3). RU, resonance
units.
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5-lipoxygenase but only moderately affect COX enzymes
(Koeberle et al., 2008b; Werz et al., 2008). Here, we have
characterized the biochemical interaction of the lead com-
pound YS121 with human mPGES-1, and we assessed its
efficacy and pharmacological profile in human whole blood
and in an animal model of inflammation. Our data demon-
strate that YS121 selectively and reversibly binds mPGES-1
as demonstrated by SPR spectroscopy and at comparable
concentrations inhibits mPGES-1 activity in a concentration-
dependent, reversible, noncompetitive manner. In human
whole blood, YS121 inhibits PGE2 formation without affect-
ing the synthesis of COX-2-derived 6-keto PGF1 and TxB2 or
COX-1-derived 12-HHT. Finally, the anti-inflammatory effi-
cacy of YS121 in vivo is demonstrated.
YS121 suppressed PGE2 formation in intact A549 cells
(Koeberle et al., 2008b) and as shown here also in human
whole blood. Cell-based test systems often fail to unequivo-
cally specify molecular targets of a given inhibitor and to
provide concrete insights into the molecular inhibitory mech-
anisms. Thus, reduced formation of PGE2 in the cell-based
assays might also be due to interference with upstream sig-
naling events (e.g., protein kinases or Ca2	 signaling) or to
modulation of the preceding substrate supply (i.e., inhibition
of phospholipase A2 or COX enzymes). However, YS121
hardly inhibited isolated COX-1 and -2 (Koeberle et al.,
2008b), and the activity of isolated cytosolic phospholipase A2
is not affected up to 10 M (M. Verhoff, C. Greiner, and O.
Werz, unpublished data). In addition, the failure of YS121 to
block the expression of mPGES-1 in A549 cells excludes
interference at the transcriptional level. Instead, YS121 di-
rectly suppressed mPGES-1 activity in a cell-free assay (mi-
crosomal preparations of IL-1-stimulated human A549
cells). Accordingly, YS121 (in contrast with indomethacin
and celecoxib) solely inhibited PGE2 formation in human
whole blood but failed to block the formation of COX-2-
derived 6-keto PGF1 and TxB2 or COX-1-derived 12-HHT.
Suppression of PGE2 formation (in cell-based models of hu-
man origin) is consequently not the result of an interruption
of the release and transformation of arachidonic acid to
PGH2 but instead relates to inhibition of PGE2 formation
from PGH2 because of interference with mPGES-1. Direct
interference of YS121 with mPGES-1 is demonstrated in two
ways: 1) by suppression of mPGES-1-mediated transforma-
tion of PGH2 to PGE2 in the cell-free assay and 2) by physical
interaction of YS121 with mPGES-1 using SPR spectroscopy,
yielding concrete data on rate constants of the association
and dissociation phase, the equilibrium constants, and the
stoichiometry. Reliable controls are obligatory for binding
studies to exclude unspecific interactions between analyte,
immobilized macromolecule, or surrounding matrix (Rich
andMyszka, 2008). In fact, at concentrations10 M, YS121
also binds to the reference dextran surface and causes aggre-
gation or micelle formation with superstoichiometric binding
pattern (Giannetti et al., 2008). Hence, binding experiments
were performed at concentrations 10 M YS121 and were
validated by using cathepsin G as an indifferent control
protein or by use of the inactive pirinixic acid as analyte. A
marked binding response was only evident between mPGES-1
and YS121, supporting a specific interaction. Investigation of
Fig. 4. Effects of YS121 on prostanoid formation in human whole blood. A, PGE2, TxB2, and 6-keto PGF1 formation. Heparinized human whole blood,
treated without (for determination of TxB2) or with 1 M thromboxane synthase inhibitor and 50 M aspirin (for determination of PGE2 and 6-keto
PGF1) was preincubated with the indicated concentrations of YS121 or vehicle (DMSO, w/o) for 5 min at room temperature, and then prostanoid
formation was induced by addition of 10 g/ml lipopolysaccharide. After 5 h at 37°C, PGE2 was extracted from plasma by RP-18 solid-phase extraction,
separated by RP-HPLC, and quantified by ELISA as described. The 100% value corresponds to 10 to 22 ng/ml PGE2 in the individual experiments,
respectively; the PGE2 levels in unstimulated blood were 1 to 3 ng/ml. MD52 (2 M) and celecoxib (20 M) were used as controls and inhibited PGE2
formation by 48  8 and 78  8%, respectively. 6-Keto PGF1 was directly determined in blood plasma by ELISA. The 100% value corresponds to 4
to 5 ng/ml 6-keto PGF1 (unstimulated 1 ng/ml) in the individual experiments, respectively. Celecoxib (20 M) inhibited 6-keto PGF1 formation by
85  4%. Indomethacin (20 M) completely inhibited TxB2 synthesis. B, 12-HHT formation. Heparinized whole blood was preincubated with YS121
or vehicle (DMSO, w/o) at the indicated concentrations for 5 min, and arachidonic acid (100 M) and Ca2	-ionophore (30 M) were added to induce
COX product formation. After 10 min at 37°C, 12-HHT was extracted and analyzed by RP-HPLC as described. The 100% value corresponds to 1 to 2
g/ml 12-HHT in the individual experiments, respectively. Indomethacin (20 M) was used as control and inhibited 12-HHT formation by 90  2%.
Data are given as mean  S.E. (n  3–4). , P  0.05; , P  0.01, versus vehicle (0.1% DMSO) control, ANOVA 	 Tukey HSD post hoc tests.
Fig. 5. Effects of YS121 on the expression of COX-2 and mPGES-1. A549
cells, 60% confluent, were incubated with 1 ng/ml interleukin-1 together
with vehicle (DMSO) or with YS121 (10 M) in cell culture medium
containing 2% (v/v) fetal calf serum. Cells were harvested after the
indicated periods, and total cell lysates were prepared and analyzed for
induction of COX-2 (72 kDa) and mPGES-1 (16 kDa) using SDS-PAGE
and Western blotting. -Actin (45 kDa) was used as loading control. Data
are representative of two independent experiments.
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the interference of YS121 with other PG synthases (e.g.,
cPGES-1 and mPGES-2) is currently limited on the basis of the
availability of such purified proteins and will be the subject of
future reports.
Because binding studies cannot discriminate between a func-
tional (i.e., enzyme inhibition) and a nonfunctional interference,
we performed kinetic studies for cell-free mPGES-1 by varying
the PGH2 and inhibitor concentrations. The calculated Km
value for PGH2 (Km  30–50 M) is consistent with results
from previous studies using purified recombinant mPGES-1
(Km  14–160 M) (Ouellet et al., 2002; Thore´n et al., 2003).
Our data indicate a noncompetitive inhibitory mechanism for
YS121as observed formyrtucommulone (Koeberle et al., 2009b) or
the dual 5-lipoxygenase-activating protein/mPGES-1 inhibitor
MK-886 (Koeberle et al., 2008a). Because of its structural fea-
ture (carboxylic acid substituted with a large lipophilic resi-
due), one may speculate that YS121 targets a postulated
fatty acid-binding site of mPGES-1 (Mancini et al., 2001;
Quraishi et al., 2002). This site might be identical to the
suggested binding site for the MK-886 derivative 3-(1-(4-
chlorobenzyl)-5-(2-fluoro-2-methylbiphenyl-4-yl)-3-methyl-
1H-indol-2-yl)-2,2-dimethylpropanoic acid (AbdulHameed et
al., 2008) or to the consensus sequence ERXXXAXXNXXD/E
to which MK-886 binds 5-lipoxygenase-activating protein
and eventually also other members of the family of mem-
brane-associated proteins in eicosanoid and glutathione me-
tabolism, including mPGES-1 (Mancini et al., 2001).
One major problem of many synthetic mPGES-1 inhibitors
relates to their strong loss of potency in whole blood assays
because of their strong plasma protein-binding tendency
(Friesen and Mancini, 2008). For example, biphenyl deriva-
tives of MK-886 are extremely potent in cell-free assays
(IC50  3 nM) but lose efficacy in presence of 50% fetal calf
serum and fail to suppress PGE2 formation in human whole
blood (Riendeau et al., 2005). In contrast, YS121 suppressed
COX-2/mPGES-1-derived PGE2 formation in human whole
blood as well as it did in the cell-free assay. However, com-
pared with indomethacin and celecoxib, YS121 and MD52
reduced PGE2 formation in lipopolysaccharide-stimulated
whole blood only partially, with maximum inhibition of 61
and 48%, respectively, even at high concentrations. Such
partial suppression of PGE2 formation was reported also for
other mPGES-1 inhibitors (Koeberle et al., 2008a, 2009a,b)
and was ascribed to the remaining PGE2 synthesis by con-
stitutively expressed PGE2 synthases (i.e., cPGES-1 and
mPGES-2). Along these lines, PGE2 levels in mPGES-1
knockout mice after injection of a noxious agent were only
reduced by 52% (Trebino et al., 2003).
Another problem with mPGES-1 inhibitors is their failure
to inhibit mPGES-1 from rodents, excluding assessment of
their in vivo efficacy in commonly used rodent models of
inflammation and pain (Friesen and Mancini, 2008). In fact,
YS121 was also less active on rodent mPGES-1 in murine
RAW264.7 cells than on human mPGES-1. Nevertheless, in
comparison with indomethacin, YS121 was as efficient in
reducing exudate formation in the pleurisy model, although
the efficacy with regard to PGE2 repression was impaired. It
should be noted that YS121 also decreased formation of
6-keto PGF1 and (in contrast with indomethacin) the pleural
levels of LTB4 to an extent similar to PGE2, implying that the
compound affects additional pathways of eicosanoid forma-
tion, such as 5-lipoxygenase (Werz et al., 2008) or may act via
PPARs (Rau et al., 2008) and thus far unknown targets.
Reduced levels of LTB4 might contribute to the overall anti-
inflammatory effectiveness of YS121, and dual inhibition of
the PG and the leukotriene synthetic pathway might syner-
gize in terms of higher anti-inflammatory efficacy and also in
terms of lower side effects (Leone et al., 2007). It is unfortu-
nate that results from experiments with mice deficient in
both mPGES-1 and 5-lipoxygenase are not available yet.
Taken together, these results indicate that binding and
kinetic approaches provided the molecular basis for the in-
hibition of human mPGES-1 by YS121 and functional studies
demonstrated suppression of PGE2 formation under inflam-
matory conditions in whole blood. Moreover, we showed the
anti-inflammatory efficacy of YS121 in an animal model of
inflammation although the exact underlying mechanisms are
unclear and the failure of YS121 (as of other mPGES-1 in-
hibitors) to efficiently inhibit rodent mPGES-1 impede as-
sessment of whether mPGES-1 inhibition contributes to the
in vivo efficacy. Based on encouraging results from mPGES-1
knockout studies (Trebino et al., 2003) and pharmacological
analysis (Xu et al., 2008), mPGES-1 inhibitors possess a high
therapeutic potential as anti-inflammatory, analgesic, and
antipyretic drugs. YS121 represents, in this respect, a prom-
ising drug candidate, because of multiple interference with
proinflammatory targets. Neither YS121 nor any other
-substituted pirinixic acid derivative was analyzed in
vivo before, and, thus, experiences regarding dosing and
pharmacokinetics (e.g., half-life, metabolism) and effec-
tiveness in humans are still missing. Ongoing preclinical
studies addressing these issues as well as the potency and
safety of YS121 will give further insights into its thera-
peutic potential.
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TABLE 1
Effect of YS121 on carrageenan-induced pleurisy in rats
Thirty minutes before intrapleural injection of carrageenan, male rats were treated intraperitoneally with YS121 (1.5 mg/kg), indomethacin (5 mg/kg), or vehicle (DMSO).
Exudate volume, PGE2, 6-keto PGF1, LTB4, and inflammatory cell accumulation in the pleural cavity were assessed 4 h after carrageenan injection. PGE2, 6-keto PGF1,
and LTB4 levels are expressed as nanograms per rat, which is the overall content of the prostanoid in the exudates. Data are given as mean  S.E. (%); n  10.
Treatment Exudate Volume Inflammatory Cells LTB4 PGE2 6-Keto PGF1
ml  106 ng/rat
Vehicle 0.40  0.03 45.2  5.2 0.99  0.12 2.48  0.28 5.54  0.55
YS121 (1.5 mg/kg) 0.15  0.026 (62)*** 27.2  1.9 (40)** 0.51  0.07 (48)*** 1.58  0.19 (36)* 3.07  0.44 (45)**
Indomethacin (5 mg/kg) 0.1  0.04 (75)*** 15.8  2.21 (65)*** 0.86  0.16 (13) 0.30  0.036 (88)*** 0.33  0.09 (94)***
* P  0.05, vs. vehicle (4% DMSO) control. ANOVA 	 Tukey HSD post hoc tests.
** P  0.01.
*** P  0.001.
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